Morgan Stanley
ENZ

Morgan Stanley’s Enzo Biochem, Inc. ENZ Stock Holding History

Morgan Stanley’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-67,342
Closed -$24.9K – 8358
2025
Q1 		$24.9K Hold
67,342
– – ﹤0.01% 6487
2024
Q4 		$48.1K Sell
67,342
-4,513
-6% -$4.68K ﹤0.01% 6298
2024
Q3 		$80.5K Buy
71,855
+100
+0.1% +$112 ﹤0.01% 6077
2024
Q2 		$78.2K Hold
71,755
– – ﹤0.01% 6048
2024
Q1 		$91.1K Sell
71,755
-79,755
-53% -$105K ﹤0.01% 6031
2023
Q4 		$211K Buy
151,510
+75,871
+100% +$101K ﹤0.01% 5927
2023
Q3 		$106K Buy
75,639
+8,000
+12% +$12.1K ﹤0.01% 5866
2023
Q2 		$124K Sell
67,639
-103,241
-60% -$239K ﹤0.01% 5848
2023
Q1 		$415K Sell
170,880
-196,422
-53% -$292K ﹤0.01% 5357
2022
Q4 		$525K Sell
367,302
-21,896
-6% -$42.7K ﹤0.01% 5222
2022
Q3 		$867K Sell
389,198
-31,558
-8% -$76.2K ﹤0.01% 4960
2022
Q2 		$871K Sell
420,756
-67,419
-14% -$167K ﹤0.01% 5100
2022
Q1 		$1.42M Buy
488,175
+469,272
+2,483% +$1.51M ﹤0.01% 4752
2021
Q4 		$60K Buy
18,903
+6,657
+54% +$22.7K ﹤0.01% 6728
2021
Q3 		$44K Sell
12,246
-1,305
-10% -$4.35K ﹤0.01% 6780
2021
Q2 		$43K Buy
13,551
+5,432
+67% +$17.1K ﹤0.01% 6734
2021
Q1 		$28K Sell
8,119
-32,530
-80% -$101K ﹤0.01% 6600
2020
Q4 		$103K Buy
40,649
+28,738
+241% +$62.6K ﹤0.01% 5901
2020
Q3 		$25K Sell
11,911
-5,787
-33% -$13.7K ﹤0.01% 5982
2020
Q2 		$39K Buy
17,698
+10,509
+146% +$27K ﹤0.01% 5763
2020
Q1 		$19K Sell
7,189
-134,535
-95% -$330K ﹤0.01% 5835
2019
Q4 		$373K Buy
141,724
+47,013
+50% +$140K ﹤0.01% 5097
2019
Q3 		$341K Buy
94,711
+31,386
+50% +$111K ﹤0.01% 4870
2019
Q2 		$213K Sell
63,325
-7,261
-10% -$25.6K ﹤0.01% 4999
2019
Q1 		$193K Sell
70,586
-90,096
-56% -$295K ﹤0.01% 5087
2018
Q4 		$447K Sell
160,682
-19,389
-11% -$63.5K ﹤0.01% 4853
2018
Q3 		$742K Sell
180,071
-47,650
-21% -$216K ﹤0.01% 4747
2018
Q2 		$1.18M Sell
227,721
-88,425
-28% -$539K ﹤0.01% 4502
2018
Q1 		$1.73M Buy
316,146
+108,944
+53% +$767K ﹤0.01% 4132
2017
Q4 		$1.69M Buy
207,202
+75,273
+57% +$719K ﹤0.01% 4173
2017
Q3 		$1.38M Buy
131,929
+73,857
+127% +$820K ﹤0.01% 4204
2017
Q2 		$640K Sell
58,072
-6,076
-9% -$56.6K ﹤0.01% 4648
2017
Q1 		$537K Sell
64,148
-86,588
-57% -$610K ﹤0.01% 4788
2016
Q4 		$1.05M Buy
150,736
+101,168
+204% +$646K ﹤0.01% 4427
2016
Q3 		$252K Sell
49,568
-26,376
-35% -$158K ﹤0.01% 4910
2016
Q2 		$453K Sell
75,944
-46,709
-38% -$259K ﹤0.01% 4488
2016
Q1 		$558K Buy
122,653
+25,435
+26% +$113K ﹤0.01% 4366
2015
Q4 		$437K Buy
97,218
+5,956
+7% +$25.2K ﹤0.01% 4633
2015
Q3 		$290K Sell
91,262
-8,040
-8% -$24.4K ﹤0.01% 4900
2015
Q2 		$301K Sell
99,302
-137,706
-58% -$387K ﹤0.01% 5028
2015
Q1 		$699K Sell
237,008
-79,666
-25% -$261K ﹤0.01% 4403
2014
Q4 		$1.41M Buy
316,674
+45,748
+17% +$218K ﹤0.01% 3863
2014
Q3 		$1.4M Buy
270,926
+36,488
+16% +$195K ﹤0.01% 3747
2014
Q2 		$1.23M Buy
234,438
+188,238
+407% +$814K ﹤0.01% 3890
2014
Q1 		$192K Sell
46,200
-60,671
-57% -$208K ﹤0.01% 5140
2013
Q4 		$313K Sell
106,871
-7,875
-7% -$19.5K ﹤0.01% 4793
2013
Q3 		$289K Buy
114,746
+10,285
+10% +$24.4K ﹤0.01% 4680
2013
Q2 		$217K Buy
+104,461
New +$231K ﹤0.01% 4801

Other funds holding ENZ

RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
KCM
Kempner Capital Management Galveston, Texas $106M AUM 29.1% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

Morgan Stanley's ENZ Position: Q2 2025 in Review

Morgan Stanley sold out of Enzo Biochem, Inc. (ENZ) in Q2 2025, closing a stake of 67,342 shares — an estimated $24.9K sold.

Morgan Stanley first reported a position in ENZ in Q2 2013 and held it in 48 quarters. The position peaked at $1.73M in Q1 2018. 6 funds tracked by Wall St. Rank hold ENZ as of Q2 2025.

  • Morgan Stanley reported no remaining Enzo Biochem, Inc. position as of Q2 2025 after selling out during the quarter.
  • Morgan Stanley sold 67,342 Enzo Biochem, Inc. shares in Q2 2025, an estimated $24.9K.
  • Morgan Stanley first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 48 quarters.
  • Morgan Stanley's Enzo Biochem, Inc. position peaked at $1.73M in Q1 2018.
  • 6 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2025.

Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.